A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Feb 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AZN SEC filings page.
AstraZeneca PLC (AZN) reported $58.7B in revenue for fiscal year 2025, up 8.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
AstraZeneca’s growth is reaching profit and cash, but reinvestment is accelerating faster than sales.
From FY2023 to FY2025, revenue rose28.2% while operating income rose67.7% , revealing operating leverage rather than simple top-line expansion. Gross margin narrowed by0.1 pp while operating margin widened by5.5 pp , placing the improvement below gross profit rather than in the reported production margin.
In FY2025, operating cash flow of
Balance-sheet improvement is visible in equity rising
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of AstraZeneca PLC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. AstraZeneca PLC scores 74/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. AstraZeneca PLC scores 72/100 on it among other operating companies.
AstraZeneca PLC's net debt of $20.8B, being $26.5B of long-term debt less $5.7B of cash, came to 1.07 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and AstraZeneca PLC scores 46/100 among other operating companies.
AstraZeneca PLC held $0.94 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 0.94. Liquidity ranks operating companies on that ratio, and AstraZeneca PLC scores 16/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. AstraZeneca PLC scores 85/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. AstraZeneca PLC scores 71/100 on it among other operating companies.
AstraZeneca PLC scores 3.65, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $286.1B against total liabilities of $65.4B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
AstraZeneca PLC passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, AstraZeneca PLC generates $1.43 in operating cash flow ($14.6B OCF vs $10.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
AstraZeneca PLC earns $8.11 in operating income for every $1 of interest expense ($13.7B vs $1.7B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
AstraZeneca PLC generated $58.7B in revenue in fiscal year 2025. This represents an increase of 8.6% from the prior year.
AstraZeneca PLC's EBITDA was $19.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.7% from the prior year.
AstraZeneca PLC reported $10.2B in net income in fiscal year 2025. This represents an increase of 45.3% from the prior year.
AstraZeneca PLC earned $6.54 per diluted share (EPS) in fiscal year 2025. This represents an increase of 45.3% from the prior year.
Cash & Balance Sheet
AstraZeneca PLC generated $11.8B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 18.4% from the prior year.
AstraZeneca PLC held $5.7B in cash against $26.5B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
AstraZeneca PLC's gross margin was 81.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.8 percentage points from the prior year.
AstraZeneca PLC's operating margin was 23.4% in fiscal year 2025, reflecting core business profitability. This is up 4.9 percentage points from the prior year.
AstraZeneca PLC's net profit margin was 17.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.4 percentage points from the prior year.
AstraZeneca PLC's ROE was 21.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.8 percentage points from the prior year.
Capital Allocation
AstraZeneca PLC invested $14.2B in research and development in fiscal year 2025. This represents an increase of 4.8% from the prior year.
AstraZeneca PLC invested $2.8B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 46.0% from the prior year.
Not reported for fiscal year 2025.
AZN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $58.7B+8.6% | $54.1B+18.0% | $45.8B+3.3% | $44.4B+18.5% | $37.4B+40.6% | $26.6B+9.2% | $24.4B+10.4% | $22.1B-1.7% | $22.5B-2.3% | $23.0B-6.9% | $24.7B |
| Cost of Revenue | $10.6B+4.2% | $10.2B+23.5% | $8.3B-33.3% | $12.4B-0.4% | $12.4B+134.7% | $5.3B+7.7% | $4.9B-0.3% | $4.9B+14.3% | $4.3B+4.7% | $4.1B-11.2% | $4.6B |
| Gross Profit | $48.1B+9.7% | $43.9B+16.8% | $37.5B+17.5% | $32.0B+27.9% | $25.0B+17.2% | $21.3B+9.5% | $19.5B+13.5% | $17.2B-5.5% | $18.1B-3.9% | $18.9B-5.9% | $20.1B |
| R&D Expenses | $14.2B+4.8% | $13.6B+24.2% | $10.9B+12.0% | $9.8B+0.3% | $9.7B+62.5% | $6.0B-1.1% | $6.1B+2.1% | $5.9B+3.0% | $5.8B-2.3% | $5.9B-1.8% | $6.0B |
| Operating Income | $13.7B+37.4% | $10.0B+22.1% | $8.2B+118.1% | $3.8B+255.8% | $1.1B-79.5% | $5.2B+76.5% | $2.9B-13.7% | $3.4B-7.9% | $3.7B-25.0% | $4.9B+19.2% | $4.1B |
| EBITDA | $19.5B+16.7% | $16.7B+22.9% | $13.6B+47.0% | $9.2B+21.8% | $7.6B-8.7% | $8.3B+24.3% | $6.7B-6.4% | $7.1B+6.4% | $6.7B-7.5% | $7.3B+4.2% | $7.0B |
| Interest Expense | $1.7B-2.8% | $1.7B+7.1% | $1.6B+20.8% | $1.3B+3.5% | $1.3B-0.5% | $1.3B-8.8% | $1.4B+0.9% | $1.4B-5.9% | $1.5B+9.0% | $1.4B+28.7% | $1.1B |
| Income Tax | $2.2B+31.5% | $1.6B+75.9% | $938.0Mn/m | -$792.0Mn/m | -$380.0M-149.2% | $772.0M+140.5% | $321.0Mn/m | -$57.0Mn/m | -$641.0M-539.0% | $146.0M-39.9% | $243.0M |
| Net Income | $10.2B+45.3% | $7.0B+18.1% | $6.0B+81.1% | $3.3B+2835.7% | $112.0M-96.5% | $3.2B+139.4% | $1.3B-38.1% | $2.2B-28.2% | $3.0B-14.2% | $3.5B+23.9% | $2.8B |
| EPS (Basic) | $6.60+45.4% | $4.54+18.2% | $3.84+81.1% | $2.12+2550.0% | $0.08-96.7% | $2.44+136.9% | $1.03-39.4% | $1.70-28.3% | $2.37-14.4% | $2.77+24.2% | $2.23 |
| EPS (Diluted) | $6.54+45.3% | $4.50+18.1% | $3.81+80.6% | $2.11+2537.5% | $0.08-96.7% | $2.44+136.9% | $1.03-39.4% | $1.70-28.3% | $2.37-14.1% | $2.76+23.8% | $2.23 |
| Diluted Shares (Avg) | 1.56B-0.1% | 1.56B+0.1% | 1.56B+0.1% | 1.56B+9.3% | 1.43B+8.7% | 1.31B+0.9% | 1.30B+2.7% | 1.27B0.0% | 1.27B+0.1% | 1.27B+0.1% | 1.26B |
Not reported in any period shown, so not listed: SG&A Expenses.
AZN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $114.1B+9.6% | $104.0B+2.9% | $101.1B+4.8% | $96.5B-8.4% | $105.4B+57.9% | $66.7B+8.7% | $61.4B+1.2% | $60.7B-4.3% | $63.4B+1.3% | $62.5B+4.1% | $60.1B |
| Current Assets | $28.7B+11.2% | $25.8B+3.1% | $25.1B+10.9% | $22.6B-13.9% | $26.2B+34.3% | $19.5B+25.6% | $15.6B-0.2% | $15.6B+18.6% | $13.2B-0.8% | $13.3B-17.1% | $16.0B |
| Cash & Equivalents | $5.7B+4.1% | $5.5B-6.0% | $5.8B-5.3% | $6.2B-2.6% | $6.3B-19.2% | $7.8B+45.9% | $5.4B+11.1% | $4.8B+45.3% | $3.3B-33.8% | $5.0B-19.6% | $6.2B |
| Inventory | $6.6B+24.0% | $5.3B-2.5% | $5.4B+15.4% | $4.7B-47.7% | $9.0B+123.2% | $4.0B+26.0% | $3.2B+10.5% | $2.9B-4.8% | $3.0B+30.0% | $2.3B+8.9% | $2.1B |
| Accounts Receivable | $15.2B+17.0% | $13.0B+7.0% | $12.1B+15.3% | $10.5B+9.1% | $9.6B+37.3% | $7.0B+21.9% | $5.8B+3.4% | $5.6B+11.3% | $5.0B+9.5% | $4.6B-30.9% | $6.6B |
| Goodwill | $21.2B+1.0% | $21.0B+4.9% | $20.0B+1.2% | $19.8B-0.9% | $20.0B+68.8% | $11.8B+1.5% | $11.7B-0.3% | $11.7B-1.0% | $11.8B+1.4% | $11.7B-1.2% | $11.8B |
| Total Liabilities | $65.4B+3.5% | $63.2B+2.0% | $62.0B+4.3% | $59.4B-10.1% | $66.1B+29.3% | $51.1B+9.2% | $46.8B+0.4% | $46.6B-0.2% | $46.7B+1.9% | $45.9B+10.4% | $41.5B |
| Current Liabilities | $30.6B+9.9% | $27.9B-8.8% | $30.5B+16.2% | $26.3B+16.4% | $22.6B+11.3% | $20.3B+12.1% | $18.1B+11.2% | $16.3B-0.6% | $16.4B+7.4% | $15.3B+2.6% | $14.9B |
| Non-Current Liabilities | $34.7B-1.6% | $35.3B+12.4% | $31.4B-5.2% | $33.1B-23.8% | $43.5B+41.2% | $30.8B+7.4% | $28.7B-5.4% | $30.3B0.0% | $30.3B-0.9% | $30.6B+14.7% | $26.7B |
| Long-Term Debt | $26.5B-5.2% | $28.0B+19.0% | $23.5B-1.8% | $23.9B-17.9% | $29.1B+60.1% | $18.2B+10.9% | $16.4B-5.5% | $17.4B+11.6% | $15.6B+7.3% | $14.5B+2.6% | $14.1B |
| Total Equity | $48.7B+19.3% | $40.8B+4.2% | $39.1B+5.7% | $37.0B-5.7% | $39.3B+151.4% | $15.6B+19.0% | $13.1B+5.3% | $12.5B-16.7% | $15.0B+0.7% | $14.9B-19.7% | $18.5B |
| Retained Earnings | $11.0B+247.2% | $3.2B+110.4% | $1.5Bn/m | -$574.0M-133.6% | $1.7B-67.7% | $5.3B+88.4% | $2.8B-50.5% | $5.7B-30.9% | $8.2B+1.0% | $8.1B-31.2% | $11.8B |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
AZN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $14.6B+22.9% | $11.9B+14.7% | $10.3B+5.5% | $9.8B+64.5% | $6.0B+24.3% | $4.8B+61.6% | $3.0B+13.4% | $2.6B-26.8% | $3.6B-13.7% | $4.1B+24.7% | $3.3B |
| Depreciation & Amortization | $5.7B-14.3% | $6.7B+24.2% | $5.4B-1.7% | $5.5B-16.1% | $6.5B+107.4% | $3.1B-16.3% | $3.8B+0.2% | $3.8B+23.6% | $3.0B+28.8% | $2.4B-17.4% | $2.9B |
| Capital Expenditures | $2.8B+46.0% | $1.9B+41.4% | $1.4B+24.7% | $1.1B0.0% | $1.1B+13.5% | $961.0M-1.8% | $979.0M-6.1% | $1.0B-21.3% | $1.3B-8.3% | $1.4B+8.9% | $1.3B |
| Free Cash Flow | $11.8B+18.4% | $9.9B+10.6% | $9.0B+3.1% | $8.7B+78.9% | $4.9B+26.9% | $3.8B+92.9% | $2.0B+26.3% | $1.6B-30.1% | $2.3B-16.6% | $2.7B+35.2% | $2.0B |
| Investing Cash Flow | -$6.8Bn/m | -$8.0Bn/m | -$4.1Bn/m | -$3.0Bn/m | -$11.1Bn/m | -$285.0Mn/m | -$657.0M-168.2% | $963.0Mn/m | -$2.3Bn/m | -$4.0Bn/m | -$4.2B |
| Financing Cash Flow | -$7.5Bn/m | -$4.0Bn/m | -$6.6Bn/m | -$6.8B-287.0% | $3.6Bn/m | -$2.2Bn/m | -$1.8Bn/m | -$2.0Bn/m | -$2.9Bn/m | -$1.3B-250.8% | $878.0M |
| Dividends Paid | $5.0B+7.4% | $4.6B+3.3% | $4.5B+2.7% | $4.4B+13.2% | $3.9B+8.0% | $3.6B-0.6% | $3.6B+3.1% | $3.5B-1.0% | $3.5B-1.2% | $3.6B+2.2% | $3.5B |
Not reported in any period shown, so not listed: Stock-Based Compensation, Share Buybacks.
AZN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9%+0.8pp | 81.1%-0.8pp | 82.0%+9.9pp | 72.1%+5.3pp | 66.8%-13.3pp | 80.1%+0.3pp | 79.8%+2.2pp | 77.7%-3.1pp | 80.8%-1.3pp | 82.1%+0.9pp | 81.2% |
| Operating Margin | 23.4%+4.9pp | 18.5%+0.6pp | 17.9%+9.4pp | 8.5%+5.6pp | 2.8%-16.6pp | 19.4%+7.4pp | 12.0%-3.3pp | 15.3%-1.0pp | 16.4%-4.9pp | 21.3%+4.7pp | 16.7% |
| Net Margin | 17.4%+4.4pp | 13.0%0.0pp | 13.0%+5.6pp | 7.4%+7.1pp | 0.3%-11.7pp | 12.0%+6.5pp | 5.5%-4.3pp | 9.8%-3.6pp | 13.4%-1.9pp | 15.2%+3.8pp | 11.4% |
| Return on Equity | 21.0%+3.8pp | 17.3%+2.0pp | 15.2%+6.3pp | 8.9%+8.6pp | 0.3%-20.2pp | 20.5%+10.3pp | 10.2%-7.1pp | 17.3%-2.8pp | 20.1%-3.5pp | 23.6%+8.3pp | 15.3% |
| Return on Assets | 9.0%+2.2pp | 6.8%+0.9pp | 5.9%+2.5pp | 3.4%+3.3pp | 0.1%-4.7pp | 4.8%+2.6pp | 2.2%-1.4pp | 3.5%-1.2pp | 4.7%-0.9pp | 5.6%+0.9pp | 4.7% |
| Current Ratio | 0.940.0x | 0.93+0.1x | 0.820.0x | 0.86-0.3x | 1.16+0.2x | 0.96+0.1x | 0.86-0.1x | 0.96+0.2x | 0.80-0.1x | 0.87-0.2x | 1.08 |
| Debt-to-Equity | 0.54-0.1x | 0.69+0.1x | 0.600.0x | 0.65-0.1x | 0.74-0.4x | 1.16-0.1x | 1.25-0.1x | 1.39+0.4x | 1.04+0.1x | 0.98+0.2x | 0.76 |
| Liabilities-to-Equity | 1.34-0.2x | 1.550.0x | 1.580.0x | 1.60-0.1x | 1.68-1.6x | 3.27-0.3x | 3.56-0.2x | 3.74+0.6x | 3.120.0x | 3.09+0.8x | 2.25 |
| Asset Turnover | 0.510.0x | 0.52+0.1x | 0.450.0x | 0.46+0.1x | 0.360.0x | 0.400.0x | 0.400.0x | 0.360.0x | 0.350.0x | 0.370.0x | 0.41 |
| FCF Margin | 20.0%+1.7pp | 18.4%-1.2pp | 19.6%0.0pp | 19.7%+6.6pp | 13.0%-1.4pp | 14.4%+6.3pp | 8.2%+1.0pp | 7.1%-2.9pp | 10.0%-1.7pp | 11.7%+3.7pp | 8.1% |
Note: The current ratio is below 1.0 (0.94), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AstraZeneca PLC AZN | FY2025 | $58.7B | $10.2B | 17.4% | $286.1B | 61/100 |
| Novartis AG NVS | FY2025 | $56.7B | $14.0B | 24.7% | $303.1B | 68/100 |
| Amgen Inc AMGN | FY2025 | $36.8B | $7.7B | 21.0% | $251.9B | 62/100 |
| Merck & Co., Inc. MRK | FY2025 | $65.0B | $18.3B | 28.1% | $364.3B | 64/100 |
| Gilead Sciences Inc GILD | FY2025 | $29.4B | $8.5B | 28.9% | $208.5B | 64/100 |
| AbbVie Inc. ABBV | FY2025 | $61.2B | $4.2B | 6.9% | $521.5B | 57/100 |
Where AstraZeneca PLC Ranks
Frequently Asked Questions
AstraZeneca PLC (AZN) reported $58.7B in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
AstraZeneca PLC (AZN) revenue grew by 8.6% year-over-year, from $54.1B to $58.7B in fiscal year 2025.
Yes, AstraZeneca PLC (AZN) reported a net income of $10.2B in fiscal year 2025, with a net profit margin of 17.4%.
AstraZeneca PLC (AZN) had EBITDA of $19.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, AstraZeneca PLC (AZN) had $5.7B in cash and equivalents against $26.5B in long-term debt.
AstraZeneca PLC (AZN) had a gross margin of 81.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
AstraZeneca PLC (AZN) had an operating margin of 23.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
AstraZeneca PLC (AZN) had a net profit margin of 17.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
AstraZeneca PLC (AZN) has a return on equity of 21.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
AstraZeneca PLC (AZN) generated $11.8B in free cash flow during fiscal year 2025. This represents a 18.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
AstraZeneca PLC (AZN) generated $14.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
AstraZeneca PLC (AZN) had $114.1B in total assets as of fiscal year 2025, including both current and long-term assets.
AstraZeneca PLC (AZN) invested $2.8B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
AstraZeneca PLC (AZN) invested $14.2B in research and development during fiscal year 2025.
AstraZeneca PLC (AZN) had a current ratio of 0.94 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
AstraZeneca PLC (AZN) had a debt-to-equity ratio of 0.54 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
AstraZeneca PLC (AZN) had a liabilities-to-equity ratio of 1.34 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
AstraZeneca PLC (AZN) had a return on assets of 9.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
AstraZeneca PLC (AZN) trades at 28.0x earnings, its market capitalization divided by $10.2B net income, FY2025. The market capitalization is $286.1B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
AstraZeneca PLC (AZN) trades at 4.9x sales, its market capitalization divided by $58.7B revenue, FY2025. The market capitalization is $286.1B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
AstraZeneca PLC (AZN) has an Altman Z-Score of 3.65, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
AstraZeneca PLC (AZN) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
AstraZeneca PLC (AZN) has an earnings quality ratio of 1.43x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
AstraZeneca PLC (AZN) has an interest coverage ratio of 8.11x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
AstraZeneca PLC (AZN) scores 61 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.